119 related articles for article (PubMed ID: 37643638)
1. In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer.
Hill D; Kaufman SR; Oerline MK; Faraj K; Caram MEV; Shahinian VB; Hollenbeck BK; Maganty A
JNCI Cancer Spectr; 2023 Jul; 7(5):. PubMed ID: 37643638
[TBL] [Abstract][Full Text] [Related]
2. Effects of In-office Dispensing by Single-specialty Urology Practices on Management of Advanced Prostate Cancer.
Lai LY; Kaufman SR; Oerline M; Caram MEV; Maganty A; Shahinian VB; Hollenbeck BK
Urol Pract; 2023 May; 10(3):230-235. PubMed ID: 37103497
[TBL] [Abstract][Full Text] [Related]
3. Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.
Lai LY; Kaufman SR; Oerline MK; Caram MEV; Maganty A; Hollenbeck BK; Shahinian VB
JNCI Cancer Spectr; 2022 Mar; 6(2):. PubMed ID: 35603854
[TBL] [Abstract][Full Text] [Related]
4. The immediate effects of private equity acquisition of urology practices on the management of newly diagnosed prostate cancer.
Faraj KS; Kaufman SR; Herrel LA; Maganty A; Oerline M; Caram MEV; Shahinian VB; Hollenbeck BK
Cancer Med; 2023 Dec; 12(24):22325-22332. PubMed ID: 38100144
[TBL] [Abstract][Full Text] [Related]
5. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
6. Understanding Prescribing Differences Between Urologists and Medical Oncologists in the Management of Advanced Prostate Cancer.
Demus T; Getzenberg RH; Nieder AM
Urol Pract; 2023 Jan; 10(1):90-97. PubMed ID: 37103443
[TBL] [Abstract][Full Text] [Related]
7. Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.
Faraj KS; Kaufman SR; Herrel LA; Maganty A; Oerline MK; Caram MEV; Shahinian VB; Hollenbeck BK
Cancer; 2024 May; 130(9):1609-1617. PubMed ID: 38146764
[TBL] [Abstract][Full Text] [Related]
8. Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis.
Malangone-Monaco E; Foley K; Varker H; Wilson KL; McKenzie S; Ellis L
Clin Ther; 2016 Aug; 38(8):1817-24. PubMed ID: 27491282
[TBL] [Abstract][Full Text] [Related]
9. Practice Competition and Treatment of Newly Diagnosed Prostate Cancer.
Maganty A; Hollenbeck BK; Kaufman SR; Oerline MK; Lai LY; Caram MEV; Shahinian VB
Urology; 2023 Jul; 177():95-102. PubMed ID: 37146728
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.
Freedland SJ; Hong A; El-Chaar N; Murty S; Ramaswamy K; Coutinho AD; Nimke D; Morgans AK
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):523-530. PubMed ID: 36517634
[TBL] [Abstract][Full Text] [Related]
11. Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.
Lai LY; Oerline MK; Caram MEV; Tsao PA; Kaufman SR; Hollenbeck BK; Shahinian VB
J Natl Cancer Inst; 2022 Aug; 114(8):1127-1134. PubMed ID: 35417024
[TBL] [Abstract][Full Text] [Related]
12. The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
Keating NL; Brooks GA; Landrum MB; Liu PH; Wolf R; Riedel LE; Kapadia NS; Jhatakia S; Tripp A; Simon C; Hsu VD; Kummet CM; Hassol A
J Natl Cancer Inst; 2022 Jun; 114(6):871-877. PubMed ID: 35134972
[TBL] [Abstract][Full Text] [Related]
13. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
[TBL] [Abstract][Full Text] [Related]
14. Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United States.
Shelton JB; Buffington P; Augspurger R; Gaylis F; Cohen T; Mehlhaff B; Suh R; Bradford TJ; Kwan L; Koo AS; Shore N
Urology; 2019 Jul; 129():79-86. PubMed ID: 30954610
[TBL] [Abstract][Full Text] [Related]
15. Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high blood cholesterol.
Iyengar RN; Balagere DS; Henderson RR; LeFrancois AL; Rabbitt RM; Frazee SG
J Manag Care Spec Pharm; 2014 Aug; 20(8):851-61. PubMed ID: 25062079
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
[TBL] [Abstract][Full Text] [Related]
17. Medication adherence among patients with advanced prostate cancer using oral therapies.
Pilon D; LaMori J; Rossi C; Durkin M; Ghelerter I; Ke X; Lafeuille MH; Ellis L; Lefebvre P
Future Oncol; 2022 Jan; 18(2):231-243. PubMed ID: 34730001
[TBL] [Abstract][Full Text] [Related]
18. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.
Franck Lissbrant I; Ventimiglia E; Robinson D; Törnblom M; Hjälm-Eriksson M; Lambe M; Folkvaljon Y; Stattin P
Scand J Urol; 2018 Apr; 52(2):143-150. PubMed ID: 29385878
[TBL] [Abstract][Full Text] [Related]
19. Trends in Medically Integrated Dispensing Among Oncology Practices.
Kanter GP; Parikh RB; Fisch MJ; Debono D; Bekelman J; Xu Y; Schauder S; Sylwestrzak G; Barron JJ; Cobb R; Qato DM; Jacobson M
JCO Oncol Pract; 2022 Oct; 18(10):e1672-e1682. PubMed ID: 35830621
[TBL] [Abstract][Full Text] [Related]
20. Urologists' use of intensity-modulated radiation therapy for prostate cancer.
Mitchell JM
N Engl J Med; 2013 Oct; 369(17):1629-37. PubMed ID: 24152262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
